Comparative analysis of the safety and efficacy of 1470-nm diode laser enucleation of the prostate and plasmakinetic resection of prostate in the treatment of large volume benign prostatic hyperplasia (>80 ml)

Abstract

Objective

To compare the efficacy and safety of 1470-nm diode laser enucleation of the prostate (DiLEP) with that of plasmakinetic resection of the prostate (PKRP) in treating patients with large benign prostatic hyperplasia (BPH > 80ml).

Methods

The clinical data from 211 cases of BPH (>80 ml) were collected for analysis. The patients were divided into two groups: the PKRP group (n = 118) and the DiLEP group (n = 93), based on the surgical method used.

Result

The DiLEP group demonstrated significantly lower surgical time (p < 0.001), intraoperative bleeding (p < 0.001), bladder flushing time (p = 0.003), indwelling catheter time (p < 0.005), and length of hospital stay (p = 0.018) compared to the PKRP group. However, the quality of the prostatectomy was significantly higher in the DiLEP group (p = 0.005). The Qmax for the DiLEP group was significantly higher than that of the PKRP group (p < 0.05). Compared to the PKRP group, the incidence of urinary incontinence in the DiLEP group increased significantly 4 weeks post-surgery (p = 0.026), although the need for blood transfusion during surgery was significantly reduced (p = 0.037).

Conclusion

Both DiLEP and PKRP are safe and effective methods for treating large-volume BPH. However, DiLEP offers advantages such as more thorough glandular resection, shorter surgical time, reduced bleeding, quicker recovery, and fewer complications.

Keywords:

• Prostate hyperplasia
• 1470-nm semiconductor laser
• PKRP
• complications
• safety

Acknowledgment

None.

Author contributions

Conceptualization: Xiao Xiao, Xiao Maolin, and Xiong Tao; Methodology and formal analysis: Deng Xiaohong, Wang Jinzhong, and Tong Wei; validation: Chen Gaoliang and Tang Mengxi; writing and editing: Xiao Xiao and Tang Mengxi; supervision: Xiao Xiao and Tang Mengxi; and funding acquisition: Xiao Xiao and Tang Mengxi.

Disclosure statement

The authors declare no competing interests.

Data availability statement

The datasets are available from the corresponding author.

Additional information

Funding

This work was supported by Chongqing Medical Scientific Research Project (Joint project of Chongqing Health Commission and Science and Technology Bureau) [Fund No. 2023MSXM158].